Photo from wikipedia
Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic… Click to show full abstract
Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.
Keywords:
inhibitor venetoclax;
chain amyloidosis;
bcl inhibitor;
immunoglobulin light;
heart transplanted;
light chain
Journal Title: Acta Haematologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Acta Haematologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!